AcuCort appoints Jonas Jönmark as new CEO
AcuCort AB (Spotlight Stock Market: ACUC) today announces that the company has finalized the process to recruit a permanent CEO and that Jonas Jönmark will assume the CEO position on August 9, 2020.
Jonas Jönmark has an MBA degree from Lund University, Sweden. He has more than 20 years’ experience from leading positions as well as the CEO role in the pharmaceutical industry and the life science sector. His career has included big international pharma companies such as Pfizer AB, Astellas Pharma A/S and Astra Zeneca Sweden, but also smaller start-up companies such as Life Science Support AB and Alteco Medical AB.
Jonas has a broad experience from international product launches, establishment of sales- and distribution channels, commercial partnerships, pricing and reimbursement negotiations with authorities as well as international business development in life science.
“I am very proud and humbled to be entrusted with the future development of AcuCort. I am looking forward to complete the market approval application for ISICORT®, the company’s first product, and the possibility to lead a successful product launch on the market,” says AcuCort’s incoming CEO Jonas Jönmark.
”I am very pleased with the recruitment of Jonas Jönmark as CEO of AcuCort. Jonas has built a solid competence in the commercialization of pharmaceutical products and his experience matches very well with AcuCort’s needs, given a possible market approval in Sweden of the company’s drug candidate ISICORT®, says Ebba Fåhraeus, Chairman of the Board of AcuCort AB.
For further information, please contact
Ebba Fåhraeus, Chairman of the Board, AcuCort AB
Phone: +46 (0)73 400 04 33
Email: [email protected]
This information is information that AcuCort AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person above, on July 16, 2020.
About AcuCort AB
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance containing – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). The bioequivalence study that forms the basis of the application for marketing approval in Europe was carried out with positive results and a national hybrid application has been submitted to the Swedish Medical Products Agency. Taken together, this strengthens the company’s assessment that the time until commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Learn more at www.acucort.com.
BrainCool AB (publ): Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2) Presented at Critical Care Reviews Trial Results Meeting
The results of trial, presented online today at Critical Care Reviews Trial Results Meeting, titled "The Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2)" which is also part of the upcoming June issue of The New England Journal of Medicine (http...
Realheart recruits CTO from German artificial heart start-up
Thomas Finocchiaro was born in Germany in 1976. He graduated from the University of Aachen, where he obtained a PhD in electrical engineering in 2012, investigating a linear drive concept for artificial hearts. He has worked for more than ten years at the University Hospital of Aachen, first as mana...
Realheart rekryterar CTO från tyska Reinheart
Thomas Finocchiaro är född 1976 i Tyskland. Han är utbildad vid universitetet i tyska Aachen, där han tog en doktorsexamen i elektroteknik 2012 med ett linjärt driftkoncept för artificiella hjärtan. Han har arbetat i mer än tio år på universi...
THERANEXUS : MINUTES OF THE COMBINED GENERAL MEETING OF 16 JUNE 2021
The general meeting adopted all the resolutions by a very large majority, with the exception of the 21st resolution concerning a delegation to increase the share capital in favor of employees who are members of a company savings plan, in accordance with the recommendation of the Board of Directors....